Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
List view / Grid view
Filter the results
By deleting the CISH gene from natural killer cells made from iPSCs, researchers say they have effectively treated leukaemia in vivo and in vitro.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Scientists in Hong Kong have developed a novel optical technique that facilitates accurate tracking of hemogenic endothelium cells in zebrafish embryos, providing new insights into the mechanisms of blood formation and potential new understanding of diseases such as leukaemia.
Researchers have identified that in leukaemia, mutated receptors allow blood stem cells to activate one another without the proper signal and suggest this discovery could lead to targeted novel therapies.
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies.
PROTAC drugs that safely and effectively target leukaemia and lymphoma cells have been developed by researchers.
A new study shows the ways in which epigenetic mechanisms control the activity of genes and may have an impact on the future treatment of certain cancers.
Researchers have found that inhibiting a kinase in mice leads to the death of prostate cancer cells, providing a potential therapeutic target.
Researchers have found a molecule, which when deleted, increases leukaemia sensitivity to natural killer cells and is a drug target.
Researchers have successfully created a multi-organ in vitro model to test toxicity and efficacy of drugs.